Interleukin-15 (IL-15) ELISA Kit
INTENDED USE
Interleukin-15 ELISA kit is intended for measuring in vitro quantitative concentrations of interleukin-15 (IL-15) in human plasma (EDTA, heparin), serum and cell culture supernatant. This assay has a minimum detection limit of < 3.0 pg/ml.
BACKGROUND
Interleukin-15 (IL-15), at maturity is able to reach 114 amino acid residues and is a modest 14-15 kDa glycoprotein that can be produced by dendritic and monocyte cells. IL-15 belongs to the four a helix bound cytokine family, other members include IL-2, IL-3, IL-5, IL-6, IL-7 and IL-9. At present the structure of IL-15 has not been determined, however, it has been predicted to be similar to IL-2 and other members of this family. The mRNA of IL-15 has been identified in monocytes, dendritic cells, epithelial cells, fibroblasts, placenta, kidneys, heart, skeletal muscle and lungs. Human IL-15 is known to display approximately 97% and 73% amino acid sequence identity with simian and mouse IL-15, respectively. Both it is found that human and simian IL-15 molecules are active with mouse cells.
This interleukin-15 ELISA kit is designed for analysing various types of diagnostic applications. Abnormal levels of IL-15 expression have been discovered in inflammatory bowel disease, rheumatoid arthritis and many diseases that have been associated with the retroviruses HIV and HTLV-I. The biological activities of IL-15 are very comparable to IL-2 such as IL-15 being able to induce the proliferation of activated CD4+, CD8+, CD4+CD8+, CD4-CD8- and dendritic epidermal T cells. The activation, development and survival of natural killer (NK) cells has been associated to IL-15. Interleukin-15 also affects the non-lymphoid tissues, such as brain, muscle, mast cells and microglia. In combination with recombinant CD40L, IL-15 can be a potent inducer of polyclonal IgA, IgG1 and IgM secretion, but it is unable to induce the production of IgE or IgG4. The use of anti-IL-15 therapy with the combination of classic immunosuppression therapy could be beneficial in the prevention or treatment of acute and especially chronic, allograft rejection. The standard used in the following interleukin-15 ELISA kit is recombinant human IL-15, consisting of 114 amino acids with the molecular mass of 12.9KDa.
SENSITIVITY
The minimum detection sensitivity level of IL-15 (interleukin-15) using current human interleukin-15 ELISA kit was approximately 3.0 pg/ml. The dynamic range for this assay is 15.6 – 1,000 pg/ml.
REFERENCES
- IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. Cancer Res. (2015) 75 (24): 5187-93. Review. Pilipow K., et al.
- Interleukin-15: new kid on the block for antitumor combination therapy. Cytokine Growth Factor Rev. (2015) 26 (1): 15-24. Van den Bergh J.M., et al.
- IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol. (2015) 15 (12): 771-83. Review. Jabri B. and Abadie V.
- Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. (2014) 10 (12): 1689-701. Review. Waldmann T.A.
- The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. (2014) 2014: 561459. Review. Wojdasiewicz P., et al.
- Therapeutic potential of IL-15 in rheumatoid arthritis. Hum Immunol. (2015) 76 (11): 812-8. Review. Yang X.K., et al.
ADDITIONAL INFORMATION
- Full Name: Interleukin-15 (IL-15) ELISA Kit
- Reactivity: Human
- Sample Type: Plasma (Heparin, EDTA), Serum, Cell Culture Supernatant
- Sensitivity: < 3.0 pg/ml
